ImmunityBio Faces Regulatory Scorn Over Unsubstantiated Cancer Treatment Claims

ImmunityBio finds itself in the crosshairs of U.S. regulators following what authorities deem to be dangerously overstated promotional claims. The U.S. Food and Drug Administration (FDA) has issued a stern formal warning to the biotechnology firm, triggering a sharp sell-off in its shares as investors reassess the company's regulatory risk.

A Sharp Market Reaction

The financial markets delivered an immediate verdict. On Tuesday, ImmunityBio shares plummeted, closing Wednesday's session at $7.42. This price point reflects a staggering single-day decline exceeding 21%, with the stock having been down nearly 27% at its intraday low. The dramatic drop underscores investor apprehension regarding potential legal and operational fallout from the regulatory confrontation.

The Core of the FDA's Complaint

The FDA's action centers on marketing materials for the company's drug, Anktiva. Currently, this therapeutic is approved solely for a specific form of bladder cancer known as non-muscle invasive bladder cancer (NMIBC). According to the agency, a television advertisement and a January 2026 podcast appearance featuring founder Dr. Patrick Soon-Shiong and CEO Richard Adcock created a profoundly misleading impression.

During an episode of "The Sean Spicer Show," the treatment was described as a pivotal molecule capable of curing cancer. The FDA explicitly criticizes these assertions of a universal cure or of utility in preventing cancer following radiation, stating they lack any clinical foundation. Furthermore, the regulator cited the omission of legally mandated risk information, including warnings about potential urinary tract infections.

A Pattern of Conduct and Escalating Response

This incident is particularly serious as it does not mark the first time the company has attracted regulatory scrutiny. The FDA had previously sent informal communications to ImmunityBio's subsidiary, Altor BioScience, in both September 2025 and January 2026. The escalation to a formal warning letter represents a significant hardening of the agency's stance, indicating diminishing patience with the company's promotional practices.

Deadlines and Divergent Perspectives

In response to the warning, ImmunityBio now has 15 working days to submit a comprehensive corrective action plan to the FDA. The company has publicly pledged its full cooperation. Failure to adequately address the concerns could result in substantial financial penalties or, in a worst-case scenario, the withdrawal of Anktiva's market authorization.

Despite the severe market setback, some analysts maintain a longer-term view of the company's value. Research firm BTIG reaffirmed its "Buy" rating on ImmunityBio stock, upholding a price target of $13. Their analysis suggests the marketing controversy does not fundamentally alter the clinical potential of the Anktiva platform. The next critical catalyst for the company is expected in the second half of 2026, with the anticipated release of new study data on Anktiva's use in BCG-naïve bladder cancer patients.

Ad

ImmunityBio Stock: New Analysis - 25 March

Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated ImmunityBio analysis...